|
 |
Kereskedelmi név |
|
|
A kereskedelmi név meghatározó jelentőségű: a készítmények összetétele
országonként, előállítóként eltérő lehet
|
|
Acetaflur |
Mexikó |
|
Asoleudox |
Mexikó |
|
Beneflur |
Mexikó, Spanyolország |
|
Fludabin |
Peru |
|
Fludacel |
India, Peru |
|
Fludakebir |
Peru |
|
Fludalym |
Törökország |
|
Fludara |
Amerikai Egyesült Államok, Ausztria, Belgium, Chile, Colombia, Dánia, Egyiptom, Finnország, Franciaország, Hollandia, India, Irán, Írország, Lengyelország, Luxemburg, Magyarország, Malaysia, Nagy-Britannia, Németország, Olaszország, Portugália, Románia, Svájc, Svédország, Szaúd-Arábiában, új-Zéland, Venezuela |
|
Fludarabin |
Izland, Norvégia, Olaszország, Svájc, Svédország |
|
Fludarabina |
Argentína, Colombia, Peru, Románia, Spanyolország |
|
Fludarabine |
Amerikai Egyesült Államok, Belgium, Irán, Kanada, Norvégia, Svájc, új-Zéland |
|
Fludarin |
India |
|
Fludarosa |
Argentína |
|
Forclina |
Peru |
|
Ludabina |
Chile, Colombia |
|
Mepredin |
Peru |
|
Naprobin |
India |
|
Neoflubin |
Irán |
|
|
 |
 |
Irodalom : Fludarabine phosphate |
|
|
Type |
publikáció |
| 3 |
Napló |
Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212. |
| 81 |
Napló |
Trissel LA, Martinez JF.
Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 672-678. |
| 84 |
Napló |
Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499. |
| 99 |
Napló |
Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090. |
| 169 |
Napló |
Trissel LA, Martinez JF.
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2359-2363. |
| 182 |
Napló |
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60. |
| 244 |
Napló |
Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913. |
| 249 |
Napló |
Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045. |
| 307 |
Napló |
Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799. |
| 492 |
Napló |
Trissel LA, Parks NPT, Santiago NM.
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2186-2189. |
| 905 |
Napló |
Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017. |
| 1410 |
Napló |
Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145. |
| 1423 |
Napló |
Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518. |
| 2344 |
Laboratórium |
Stabilité physico-chimique de la gamme oncologie Ebewe Pharma France après dilution.
Ebewe Pharma 2009 |
| 3306 |
Napló |
Trittler R.
New stability studies for fludarabine according to the European Pharmacopoeia 7.0
EJOP 2012 ; 6, 1: 1-2. |
| 3595 |
Laboratórium |
Aciclovir - Summary of Product Characteristics
Hospira 2009 |
| 3604 |
Laboratórium |
Daunorubicine (Cérubidine®) - Résumé des caractéristiques du produit
Sanofi Aventis France 2012 |
| 3637 |
Laboratórium |
Methotrexate (Methotrexate solution for injection®) - Summary of Product Characteristics
Hameln Pharmaceuticals 2014 |
| 3644 |
Laboratórium |
Calcium gluconate® - Summary of Product Characteristics
Hameln Pharmaceuticals 2010 |
| 3670 |
Napló |
Sewell G, Massimini M.
Studies on the stability and compatibility of cytotoxic drug infusion with the Tevadaptor system.
EJOP 2014 ; 8, 3: 26-30. |
| 3838 |
Laboratórium |
Magnesium Sulphate - Summary of Product Characteristics
Martindale Pharmaceuticals Ltd 2007 |
| 4398 |
Napló |
Smith E. K., Shergold J.A., McWhinney B.C.
Compatibility of intravenous busulfan with BBraun giving sets, fludarabine and Posiflush.
J Pharm Pract and Res 2020 |
|
|
